Articles tagged "Monitoring"

2022 American Transplant Congress
Circulating Donor-Derived Cell-Free DNA: A Novel Non-Invasive Biomarker for Immune Surveillance in Vascularized Composite Allotransplantation
W. J. Rifkin¹, J. Trilles¹, P. S. Rabbani¹, O. C. Onuh¹, B. E. Gelb², D. J. Ceradini¹, E. D. Rodriguez¹
¹Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, ²Transplant Institute, NYU Langone Health, New York, NY
*Purpose: The purpose of this study is to evaluate whether circulating donor-derived cell-free DNA (dd-cfDNA) could be used as a noninvasive biomarker to detect rejection…
2022 American Transplant Congress
Clinical Validation of Automated Urinary Chemokine Assays for Non-Invasive Detection of Kidney Transplant Rejection: A Large Prospective Cohort Study
E. Van Loon¹, C. Tinel¹, J. Callemeyn¹, M. Coemans¹, A. Van Craenenbroeck¹, T. Vaulet², D. Anglicheau³, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²ESAT STADIUS Center for Dynamical Systems, KU Leuven, Leuven, Belgium, ³Department of Nephrology and Kidney Transplantation, Necker Hospital, Paris, France
*Purpose: Non-invasive diagnostic markers for kidney transplant rejection can provide useful information but often do not reach the clinical implementation stage. The chemokines CXCL9 and…
2022 American Transplant Congress
Biological Functions of Circulating miRNAs in Patients with Chronic Pancreatitis Undergoing Total Pancreatectomy with Islet Autotransplantation
S. Vasu¹, C. Darden², Y. Liu³, M. Lawrence⁴, B. Naziruddin¹
¹Baylor University Medical Ctr, Dallas, TX, ²Baylor University, Waco, TX, ³-Baylor University Medical Center, Dallas, TX, ⁴Baylor University Medical Center, Dallas, TX
*Purpose: Our previous reports showed that in patients with Chronic Pancreatitis (CP), specific microRNAs (miRNA) were elevated in circulation before, during islet infusion and after…
2022 American Transplant Congress
Utility of a Holistic Molecular Paradigm for Kidney Biopsy in the Clinic
S. Anand¹, J. Sanchez-Garcia¹, K. Qui², K. Pinney², A. Raza¹, T. Srinivas², D. Morris¹
¹Intermountain Medical Center, Murray, UT, ²CareDX, South San Francisco, CA
*Purpose: We report on the clinical utility of a serial dd-cfDNA (donor derived cell free DNA) monitoring coupled with Tissue Transcriptomics (Tr) and Histology (Hx)…
2022 American Transplant Congress
The Trajectory of Donor-Derived Cell-Free DNA (dd-cfDNA) Complements the Baseline Measurements in Heart Transplant Surveillance for Rejection
P. Shah¹, R. Cheng², H. Eisen³, B. D. Lowes⁴, L. Lourenco Jenkins⁵, Y. Fu⁵, K. Qu⁵, J. Teuteberg⁶, E. DePasquale⁷
¹Inova Heart and Vascular Institute, Falls Church, VA, ²University of Washington Heart Institute, Seattle, WA, ³Pennsylvania State University, Hershey, PA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵CareDx, Brisbane, CA, ⁶Stanford University, Stanford, CA, ⁷University of Southern California, Los Angeles, CA
*Purpose: Changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the dd-cfDNA…
2022 American Transplant Congress
Implementation of Infectious Disease Surveillance in Recently Deceased Human Xenograft Study
S. J. Cawthon, E. P. Weldon, N. S. Lawson, B. E. Lonze, R. A. Montgomery, S. A. Mehta
NYU Langone Transplant Institute, New York, NY
*Purpose: Xenotransplantation is a promising solution for the ongoing organ shortage but has been slow to develop because of both immunological challenges and potential risk…
2022 American Transplant Congress
A Composite Endpoint to Improve Upon the Srtr 5-Tier Rating System
R. Formica¹, K. Wang², Y. Deng², D. Stewart³
¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³UNOS, Richmond, VA
*Purpose: Kidney transplant program performance in the US is monitored with outcome metrics used by regulatory agencies to assess provider quality and by patients to…
2022 American Transplant Congress
Delta Changes in Donor-Derived Cell-Free DNA (dd-cfDNA) Complement the Donor Fraction in Kidney Transplant Surveillance
A. Wiseman¹, M. Jagadeesan², G. Gupta³, V. Rao⁴, M. Narayanan⁵, N. Agrawal⁶, G. Shekhtman⁶, Y. Fu⁶, K. Pinney⁶, S. Anand⁷
¹Centura Health, Denver, CO, ²George Washington University, Washington, DC, ³Virginia Commonwealth University, Richmond, VA, ⁴Medical University of South Carolina, Charleston, SC, ⁵Baylor Scott and White, Austin, TX, ⁶CareDx, Brisbane, CA, ⁷Intermountain Healthcare, Murray, UT
*Purpose: Delta changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the…
2022 American Transplant Congress
Technology Enabled And Molecular Monitoring Of The Allograft And Transplant Recipient Study
N. Sulejmani¹, D. Axelrod², S. Dholakia¹, S. Shah³
¹CareDx, South San Francisco, CA, ²University of Iowa, Iowa City, IA, ³University of Cincinnati, Cincinnati, OH
*Purpose: With the widespread availability of smart mobile devices, mobile health (mHealth) provides the opportunity to reach wide array of patients. Readmission rates as high…
2022 American Transplant Congress
Surveillance with Allosure for Allograft Rejection and Infection in Lung Transplant
M. M. Botros¹, N. Sulejmani², B. F. Reader³, B. C. Keller¹
¹Pulmonary, Critical Care & Sleep Medicine, The Ohio State University, Columbus, OH, ²Medical Affairs, CareDx, South San Francisco, CA, ³Division of Transplant Surgery, The Ohio State University, Columbus, OH
*Purpose: Measurement of plasma donor-derived cell-free DNA (dd-cfDNA; AlloSure, CareDx) has been shown to be a useful non-invasive diagnostic test for injury and infection after…

1
2
3
…
22
Next Page »